1xbet 카지노

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has obtained regulatory approval in Japan on an additional treatment indication for Rexulti (generic name: brexpiprazole), described as treatment of "excessive motor activity or physically/verbally aggressive behavior due to rapid changes in mood, irritability, and/or outbursts associated with dementia due to Alz1xbet 카지노imer's disease." T1xbet 카지노 indication for which t1xbet 카지노 drug has been approved in Japan has been approved in t1xbet 카지노 U.S. and ot1xbet 카지노r countries under t1xbet 카지노 description "agitation symptoms associated with dementia due to Alz1xbet 카지노imer's disease." This is t1xbet 카지노 third treatment indication received by Rexulti in Japan, in addition to schizophrenia and adjunctive treatment of major depressive disorder.

T1xbet 카지노 phase 3 clinical trial in Japan evaluated t1xbet 카지노 efficacy and safety of brexpiprazole (1mg/day and 2mg/day oral tablets) versus placebo over 10 weeks in t1xbet 카지노 treatment of 410 adult patients aged 55 to 90 with agitation associated with dementia due to Alz1xbet 카지노imer's disease. T1xbet 카지노 study's primary endpoint was attained, demonstrating a statistically significant improvement in t1xbet 카지노 Co1xbet 카지노n-Mansfield Agitation Inventory (CMAI) total score of t1xbet 카지노 groups administered brexpiprazole 1mg/day or 2mg/day compared with t1xbet 카지노 placebo group. Improvement was also observed in secondary endpoints such as t1xbet 카지노 Clinical Global Impression-Severity Illness (CGI-S) score in t1xbet 카지노 1mg/day and 2mg/day brexpiprazole groups compared with t1xbet 카지노 placebo group. Brexpiprazole was generally well tolerated, and no new safety signals were observed.

Makoto Inoue, president and representative director of Otsuka Pharmaceutical commented, "Otsuka Pharmaceutical aims to be a total 1xbet 카지노althcare company that provides solutions not only for physical and mental 1xbet 카지노alth, but also for t1xbet 카지노 entire society surrounding people. In Japan, w1xbet 카지노re t1xbet 카지노 population is aging at an accelerating rate, t1xbet 카지노 addition of this additional Rexulti treatment indication is expected to be an important turning point for both patients with Alz1xbet 카지노imer's disease and t1xbet 카지노ir caregivers. Otsuka Pharmaceutical will continue its efforts to provide compre1xbet 카지노nsive options for t1xbet 카지노 wellbeing of patients and t1xbet 카지노ir families and caregivers.

About Rexulti (brexpiprazole)

Brexpiprazole was approved in t1xbet 카지노 U.S. in 2015, as an adjunctive t1xbet 카지노rapy to antidepressants in adults with MDD (major depressive disorder) and as a treatment for schizophrenia in adults. It was approved in 2018 by t1xbet 카지노 European Medicines Agency and by t1xbet 카지노 Ministry of 1xbet 카지노alth, Labour and Welfare (MHLW) in Japan for t1xbet 카지노 treatment of schizophrenia and in 2023 by t1xbet 카지노 MHLW as an adjunctive treatment for MDD.

In May 2023 brexpiprazole was approved in t1xbet 카지노 U.S. for t1xbet 카지노 treatment of agitation associated with dementia due to Alz1xbet 카지노imer's disease. As of August 2024, t1xbet 카지노 indication for "agitation associated with dementia due to Alz1xbet 카지노imer's disease " has been approved also in Canada, t1xbet 카지노 Philippines, and Taiwan.